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A patient with acute stroke has just been admitted who 
is immobile, and cannot walk to the bathroom without 
help. Looking at the patient’s unmoving legs the risk 
of thrombosis is clear, but a low molecular weight 
heparin (LMWH) might lead to bleeding, and elastic 
compression stockings cause skin problems. So you 
settle on intermittent pneumatic compression devices 
(IPCs)—but do they actually prevent blood clots?
Decades after IPCs were ﬁ rst reported to prevent 
venous thromboembolism (VTE) in surgical patients, 
Martin Dennis and colleagues1 present the results of 
the randomised CLOTS 3 trial in The Lancet, showing 
that IPCs reduce the risk of VTE in immobilised medical 
inpatients who have had a stroke.
VTE is among the most signiﬁ cant complications 
associated with hospital stay.2 Several entities recom-
mend strategies to prevent hospital-acquired VTE;3,4 
indeed, the US Center for Medicare Services does not 
compensate hospitals for treating VTEs acquired in 
hospital or diagnosed in the month after discharge. Yet 
VTE prevention measures are persistently underused, 
and their use is substantially lower in medical 
inpatients than in surgical inpatients.5 Is it surprising 
that three-quarters of hospital-acquired VTEs occur in 
medical patients?6
There are several reasons doctors fail to provide 
prophylaxis. One could simply forget; or hesitate to use 
an anticoagulant because of a fear of excessive ble ed-
ing. Medical patients often have disorders that place 
them at high risk of bleeding and can require inva-
sive procedures, sometimes at short notice. Although 
regulatory bodies dictate use of pharmacological 
prophyl axis in ever-larger populations of medical 
inpatients, recent trials have shown a very tight balance 
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survived 2 weeks or more after subcortical lacunar 
ischaemic stroke. Systolic blood pressure should be 
lowered gradually and cautiously, in view of the potential 
for serious complications related to hypotension. 
Researchers should assess further the safety and eﬀ ective-
ness of this target in survivors of other ischaemic stroke 
subtypes and of haemorrhagic stroke, and continue to 
explore the eﬀ ects of blood-pressure lowering in patients 
with acute ischaemic or haemorrhagic stroke.14,15
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between preventing VTE and causing bleeding.7 
In patients who have had a stroke, anticoagulant 
prophylaxis causes a 0·6% absolute increase in major 
bleeding, whereas the degree of protection against VTE 
is debated.7,8 IPCs, which do not increase bleeding risk, 
are therefore attractive.
IPCs are often used in non-surgical patients, on the 
basis of indirect evidence from surgical populations. 
However, the beneﬁ ts seen in surgical patients cannot 
be assumed to translate to medical patients. Elastic 
compression stockings were reported to cause net 
harm in patients who have had a stroke,9,10 despite 
studies showing net beneﬁ t in surgical patients. Direct 
evidence has been needed. To our knowledge, CLOTS 3 
is the highest quality, and by far the largest, study to 
date of IPC use for VTE prophylaxis in non-surgical 
patients. It enrolled immobile (ie, unable to walk to 
the toilet without assistance) patients admitted with 
stroke. Patients were randomly assigned to either 
not receive IPC or to receive open-label IPCs (given 
the impracticality of masking this intervention), 
which were continued for a minimum of 30 days, 
until the patient regained mobility or was discharged. 
Background prophylaxis with additional methods 
was allowed, and anticoagulant prophylaxis or 
therapeutic anticoagulation was given to about 
a third of patients in both intervention groups. 
118 (8%) of 1438 patients allocated IPCs and 42 (3%) 
of 1438 control patients also used elastic stockings. 
Thrombotic outcomes were assessed by mandatory 
screening ultrasound on days 7–10 and 25–30 and by 
objective assessment if VTE symptoms arose. Masked 
assessors did the ultrasounds. The investigators paid 
careful attention to the randomisation scheme, and 
patients’ characteristics were well balanced between 
study groups.
IPC use resulted in an absolute risk reduction of 3·6% 
(95% CI 1·4–5·8) of the primary outcome of all proximal 
deep vein thrombosis (DVT) by day 30 compared with 
no IPC use. Most other thrombotic outcomes were also 
signiﬁ cantly reduced with IPC use. Although the trial was 
not powered to show a signiﬁ cant reduction in either 
pulmonary embolism or death, the IPC group appeared 
to be favoured compared with the no IPC group. Skin 
breaks occurred more frequently in the IPC group than in 
the no IPC group, and a non-signiﬁ cant increase in falls 
with injury was noted in the IPC group.
The trial has several limitations. The prospective, 
randomised, open, blinded endpoint (PROBE) design is 
subject to bias, but a double-blind design for an IPC study 
would be impractical. Both the size of the study and 
the design of the IPC device were changed during trial 
execution; but neither change is likely to have materially 
aﬀ ected the results. The rate of symptomatic (vs 
asymptomatic) DVT was unexpectedly high, which could 
be attributed to the method of ascertainment (clinicians 
were asked to indicate if DVT symptoms were present 
after completion of the scheduled screening ultrasound 
tests). Had more traditional methodology been used, 
more DVTs would have been classiﬁ ed as asymptomatic, 
and a smaller reduction in symptomatic DVT would 
probably have been reported. How well asymptomatic 
DVT predicts the risk of symptomatic VTE is debated, but 
asymptomatic DVT is a common trial endpoint.11
IPCs are hard to keep on patients;12 and adherence 
issues were noted in the trial. Perfect adherence (IPC use 
for the entire intended duration) occurred in less than a 
third of patients. Moreover, adherence was monitored 
by nurses who were asked to assess IPC use three 
times a day; yet adherence was counted in whole days. 
This method probably yielded an incomplete picture of 
actual device use. Outside a trial, IPC adherence might be 
even worse, leading to less beneﬁ t. Future studies should 
explore methods to improve device compliance, and 
could use technology that continually monitors IPC use.13
Nonetheless, CLOTS 3 has convinced us, and we will 
prescribe IPCs to patients who have had a stroke and are 
immobile in hospital. The beneﬁ t of IPCs in reducing VTE 
outweighs the risk of skin complications. More studies 
of IPCs in other medical inpatients are needed, but it 
could be years until similar high-quality evidence is 
available. Until then, CLOTS 3 provides reassurance to 
clinicians who choose to prescribe IPCs to immobilised 
medical inpatients without stroke.
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The association between nutrition in early life and 
long-term health has been of interest for decades. 
Since the articulation of the fetal origins hypothesis by 
David Barker and colleagues,1 there has been debate 
about the implications of fetal undernutrition and 
early childhood growth on outcomes of importance 
in adult health and risks of chronic diseases. Both 
epidemiological and animal studies have shown that 
the risk of metabolic syndrome is signiﬁ cantly increased 
after exposure to suboptimum nutrition during crucial 
periods of development.1 The importance of these 
ﬁ ndings greatly increased after reports about the global 
burden of non-communicable diseases and risk factors 
were published in December, 2012.2
Evidence for the importance of early nutrition for 
adult outcomes was derived initially from obser-
vational cohort studies3 and was reaﬃ  rmed by analysis 
of outcome data from several cohort studies in 2008.4 
This analysis4 was focused on a meta-analysis of 
coeﬃ  cients from diﬀ erent sites: birthweight, weight 
and length Z scores, and stunting at age 2 years. 
In The Lancet, Linda Adair and colleagues5 report 
ﬁ ndings from a study in which they pooled data 
from ﬁ ve birth cohorts and investigated how linear 
growth and relative weight gain in several age ranges 
aﬀ ected adult outcomes. They report that higher 
birthweight was associated with an adult body-mass 
index of greater than 25 kg/m² (odds ratio 1·28, 
95% CI 1·21–1·35) and a reduced likelihood of short 
stature (0·49, 0·44–0·54) and of not completing 
secondary school (0·82, 0·78–0·87). Faster linear 
growth was also strongly associated with reduced 
likelihood of short adult stature (age 2 years: 0·23, 
0·20–0·52; mid-childhood 0·39, 0·36–0·43) and of 
not completing secondary school (age 2 years: 0·74, 
0·67–0·78; mid-childhood 0·87, 0·83–0·92). Faster 
relative weight gain was associated with an increased 
risk of adult overweight (age 2 years: 1·51, 1·43–1·60; 
mid-childhood 1·76, 1·69–1·91) and elevated blood 
pressure (age 2 years: 1·07, 1·01–1·13; mid-childhood: 
1·22, 1·15–1·30).
Notwithstanding the key ﬁ ndings, several limit-
ations of this pooled analysis should be recognised. 
The authors had to make do with disparate 
information about socio economic status and income, 
and impute some information that was missing. 
Although they adjusted for maternal education and 
socioeconomic status (largely assets rather than 
income), other potential confounding factors (eg, 
household and learning environment) could not be 
assessed in relation to attained schooling. Several 
additional limitations preclude ﬁ rm con clusions. 
Little or no information was available about maternal 
nutrition and micronutrient status. Additionally, Adair 
and colleagues do not report any outcomes related to 
intrauterine growth retardation or gestational age at 
birth, and merely report association with birthweight, 
which might be oversimpliﬁ ed. Being small for 
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